OncoDaily Newsletter
Subscribe to our newsletter
ASCO Updates Breast Cancer Follow-Up Guidelines With Risk-Based Surveillance Approach
RICE Study: Can Immune Checkpoint Inhibitors Be Used Again After Progression?
Vincent Rajkumar: Limited Duration of Lenalidomide Maintenance is Just as Good as Indefinite Therapy
The System Behind Access of New Cancer Drugs with Lisa Thompson Smith
The Thirteen-Minute Infusion: What Sarclisa's Wearable Injector Signals for Cancer Care
Durvalumab With Radiation Shows Promise in Chemotherapy-Ineligible Locally Advanced NSCLC
Lovett Evan Reddick: Honored to Join GSK as Executive Director, Emerging Therapeutic Areas
Tucatinib Plus Trastuzumab Deruxtecan Shows Activity but No Clear Added Benefit in HER2+ Advanced Breast Cancer
